AI assistant
Emergent BioSolutions Inc. — Director's Dealing 2017
May 26, 2017
32870_dirs_2017-05-26_5f515d1c-a236-4211-a502-64c1c7ef69fc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2017-05-25
Reporting Person: SULLIVAN LOUIS W (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-08-01 | Common Stock | J | 152 | — | Acquired | 34637 | Direct |
| 2016-08-01 | Common Stock | J | 604 | — | Acquired | 35241 | Direct |
| 2016-08-01 | Common Stock | J | 577 | — | Acquired | 35818 | Direct |
| 2017-05-25 | Common Stock | A | 8259 | $0.00 | Acquired | 40077 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-08-01 | Employee Stock Option (Right to buy) | $14.71 | J | 693 | Acquired | 2020-05-20 | Common Stock (7893) | Direct |
| 2016-08-01 | Employee Stock Option (Right to buy) | $20.08 | J | 693 | Acquired | 2021-05-19 | Common Stock (7893) | Direct |
| 2016-08-01 | Employee Stock Option (Right to buy) (Common Stock) | $13.37 | J | 693 | Acquired | 2019-05-17 | Common Stock (7893) | Direct |
| 2016-08-01 | Employee Stock Option (Right to buy) (Common Stock) | $13.00 | J | 693 | Acquired | 2020-05-23 | Common Stock (7893) | Direct |
| 2016-08-01 | Employee Stock Option (Right to buy) (Common Stock) | $18.64 | J | 905 | Acquired | 2021-05-22 | Common Stock (10305) | Direct |
Footnotes
F1: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017.
F2: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018.
F3: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.
F4: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
F5: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date.
F6: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
F7: The option grant is fully vested.